Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Glenmark Pharmaceuticals Limited — Q4 FY25
Glenmark's Q4 FY25 consolidated revenue grew 6.3% YoY to INR 3,256 crore, with full-year revenue up 12.8% to INR 13,322 crore.
neutral
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Glenmark's Q4 FY25 consolidated revenue grew 6.3% YoY to INR 3,256 crore, with full-year revenue up 12.8% to INR 13,322 crore. Adjusted PAT was INR 246.6 crore (margin 10.6%). India formulation sales were flat (+0.4% YoY) due to weak acute respiratory demand, competitive diabetes market, and discontinuation of low-margin brands. Europe grew 20% YoY, driven by branded respiratory portfolio and Ryaltris. North America declined 5.4% due to lack of meaningful launches, but management expects an uptick from H1 FY26 with generic Flovent and nasal spray approvals. Management guided FY26 revenue growth of 10%-12%, EBITDA margin of 19%-20%, and cash generation of INR 300-400 crore. Key risks include delayed U.S. launches, FDA compliance issues at Pithampur and Monroe plants, and continued diabetes portfolio erosion in India.
ग्लेनमार्क की चौथी तिमाही (जनवरी-मार्च 2025) में कुल कमाई पिछले साल से 6.3% बढ़कर 3,256 करोड़ रुपये हो गई। पूरे साल की कमाई 12.8% बढ़कर 13,322 करोड़ रुपये रही। कंपनी का शुद्ध मुनाफा 246.6 करोड़ रुपये (10.6% मार्जिन) था। भारत में दवाओं की बिक्री सपाट रही, क्योंकि सर्दी-खांसी की दवाओं की मांग कम थी, डायबिटीज बाजार में कड़ी प्रतिस्पर्धा थी, और कम मुनाफे वाले उत्पाद बंद कर दिए गए। यूरोप में बिक्री 20% बढ़ी, खासकर सांस की दवाओं और रायल्ट्रिस के कारण। उत्तरी अमेरिका में बिक्री 5.4% गिरी, लेकिन कंपनी को उम्मीद है कि नई दवाओं (जेनेरिक फ्लोवेंट और नेज़ल स्प्रे) के लॉन्च से अगले साल की पहली छमाही में सुधार होगा। कंपनी ने अगले साल 10-12% कमाई बढ़ोतरी, 19-20% मुनाफा मार्जिन और 300-400 करोड़ रुपये नकदी जुटाने का लक्ष्य रखा है। जोखिमों में अमेरिका में देरी, फैक्ट्रियों में एफडीए की मंजूरी में रुकावट और भारत में डायबिटीज दवाओं की बिक्री गिरना शामिल
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
U.S. FDA compliance issues at Pithampur and Monroe plants
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Ryaltris global sales
$80M
+100% YoY
Ryaltris sales doubled from $40M in FY24; expected to cross $100M in FY26.
India secondary sales growth (IQVIA)
10.3%
+3.4pp vs IPM
Glenmark's India formulation secondary sales grew 10.3% in Q4, outperforming IPM growth of 6.9%.
IGI annual burn rate
$70M
flat
IGI's annual expenditure is ~$70M; expected to be covered by licensing deal for ISB 2001.
Net working capital days
104 days
flat
Net working capital stood at 104 days of sales, in line with global peers.
What Changed vs Last Quarter
NEW
Revenue growth 10%-12% in FY26
Consolidated revenue from operations expected to grow 10%-12% year-over-year in FY2026.
NEW
EBITDA margin 19%-20% in FY26
EBITDA margin guided to 19%-20% for FY2026, driven by Ryaltris, U.S. launches, and R&D efficiencies.
NEW
Cash generation INR 300-400 crore in FY26
Free cash flow (post-interest and dividends) expected to be INR 300-400 crore in FY2026.
NEW
Generic Flovent 44 mcg approval by end of Q2 FY26
Expects approval for generic Flovent 44 mcg strength by end of Q2 FY2026, with launch thereafter.
DROPPED
India business to achieve 9-10% growth for FY25
Management reiterated guidance of INR 1,100 crore per quarter average, implying 9-10% YoY growth for the full year.
DROPPED
EBITDA margin improvement of 1-1.5% YoY
Management expects year-on-year EBITDA margin improvement of 1-1.5% going forward, driven by critical launches.
DROPPED
Fluticasone 44 MDI approval in H1 FY26
The company expects approval for Fluticasone 44 mcg MDI in the first half of FY26, with potential for earlier approval.
DROPPED
IGI to be self-funded from FY27 onwards
Management expects FY26 to be the last year of Glenmark's capital investment in IGI, with a partnership expected to fund IGI going forward.
NEW RISK
U.S. FDA compliance issues at Pithampur and Monroe plants
Pithampur plant under FDA discussion; Monroe plant awaiting inspection. Delays could impact U.S. launch timelines.
NEW RISK
Diabetes portfolio erosion in India
Remogliflozin and Teneligliptin, which contributed ~60% of diabetes sales, faced generic competition; new launches (Lirafit, Empagliflozin) yet to fully offset decline.
NEW RISK
Delayed U.S. launches and lack of meaningful approvals
North America revenue declined 5.4% due to back-ended launches; Flovent and nasal spray approvals may slip further.
NEW RISK
IGI licensing deal uncertainty
ISB 2001 licensing deal is critical to fund IGI's $70M annual burn; any delay could pressure margins.
RISK GONE
US FDA inspection delay at Monroe plant
The Monroe facility is awaiting FDA inspection, delaying potential revenue from injectable products. Management has limited visibility on timing.
RISK GONE
Currency headwinds in emerging markets
Adverse currency movements in LATAM, South Africa, and Russia impacted reported growth and EBITDA margins by approximately INR 71 crore in Q3.
RISK GONE
India business slowdown in acute respiratory
Q3 India formulation growth was impacted by a slowdown in acute respiratory sales, though management expects recovery in Q4.
RISK GONE
Competition in GLP-1 market
The Indian GLP-1 market is expected to become crowded, potentially limiting Glenmark's market share despite its first-mover advantage with Lirafit.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24, Q3 FY25
Q3 India formulation growth was impacted by a slowdown in acute respiratory sales, though management expects recovery in Q4.
Mentioned in Q1 FY24, Q2 FY24
Europe business expected to grow at a minimum of 15-20% going forward, driven by respiratory portfolio and Ryaltris.
Mentioned in Q1 FY25, Q3 FY25
The Indian GLP-1 market is expected to become crowded, potentially limiting Glenmark's market share despite its first-mover advantage with Lirafit.
Mentioned in Q1 FY25, Q2 FY25
Management aims to initiate partnering discussions post-ASH 2024 and expects a deal by FY26.
Mentioned in Q2 FY24, Q4 FY24
Remediation completed but FDA reinspection pending; delay could impact injectable commercialization timeline.
Fast read
Guidance and risk preview
Consolidated revenue from operations expected to grow 10%-12% year-over-year in FY2026.
Pithampur plant under FDA discussion; Monroe plant awaiting inspection.
View Risks →